Xilio Therapeutics
36 hedge funds and large institutions have $18.6M invested in Xilio Therapeutics in 2025 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 3 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
15% more capital invested
Capital invested by funds: $16.2M → $18.6M (+$2.43M)
3% more funds holding
Funds holding: 35 → 36 (+1)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0.24% less ownership
Funds ownership: 3.28% → 3.04% (-0.24%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$86.2K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$74.8K |
| 3 |
Squarepoint
New York
|
+$66.8K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$29.6K |
| 5 |
Renaissance Technologies
New York
|
+$29K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
-$906K |
| 2 |
Morgan Stanley
New York
|
-$345K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$162K |
| 4 |
APP
Avantax Planning Partners
Dubuque,
Iowa
|
-$96.8K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$29.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Raymond James Financial
St Petersburg,
Florida
| $15.8K | – | – | – |
|
|
27
UBS Group
Zurich,
Switzerland
| $11.5K | -$162K | -16,166 | -94% |
|
|
DF
28
Dunhill Financial
London,
United Kingdom
| $8.66K | – | – | – |
|
|
IAMOG
29
Investors Asset Management of Georgia
Atlanta,
Georgia
| $8.43K | – | – | – |
|
|
PFG
30
Pinnacle Financial Group
Western Springs,
Illinois
| $8.43K | – | – | – |
|
|
FDCDDQ
31
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $2.78K | – | – | – |
|
32
BlackRock
New York
| $1.72K | – | – | – |
|
|
KFI
33
Key Financial Inc
West Chester,
Pennsylvania
| $691 | – | – | – |
|
|
PWMG
34
Private Wealth Management Group
Princeton,
New Jersey
| $262 | – | – | – |
|
35
Citigroup
New York
| $217 | +$180 | +18 | New |
|
36
Bank of America
Charlotte,
North Carolina
| $207 | -$60 | -6 | -25% |
|
|
GCM
37
Ghisallo Capital Management
Boston,
Massachusetts
| – | -$906K | -95,214 | Closed |
|
|
APP
38
Avantax Planning Partners
Dubuque,
Iowa
| – | -$96.8K | -10,167 | Closed |
|
|
TRCT
39
Tower Research Capital (TRC)
New York
| – | -$10.5K | -1,101 | Closed |
|
XLO Hedge Fund Activity: Q3 2025 in Review
36 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q3 2025, worth a combined $18.6M — up 15% from $16.2M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new XLO positions and 3 closed out — a net gain of 1 holder — while 6 added to existing stakes and 4 trimmed.
The largest buyer was State Street, adding an estimated $86.2K. The largest seller was Ghisallo Capital Management, exiting entirely with an estimated $906K sold.
- 36 institutional investors held Xilio Therapeutics (XLO) as of Q3 2025, up from 35 in Q2 2025.
- Funds reported $18.6M of Xilio Therapeutics stock for Q3 2025, up 15% quarter-over-quarter.
- 4 funds opened new Xilio Therapeutics positions in Q3 2025 and 3 closed out, a net change of +1 holder.
- The largest Xilio Therapeutics buyer in Q3 2025 was State Street, an estimated $86.2K added.
- The largest Xilio Therapeutics seller in Q3 2025 was Ghisallo Capital Management, an estimated $906K sold.
Based on aggregated 13F filings for Q3 2025.